Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Gilead still eyeing cancer, inflammation deals

    Gilead Sciences Inc. (NASDAQ:GILD) reported earnings that showed a continued reliance on HCV sales and company executives expressed interest in dealmaking to broaden Gilead's cancer and inflammatory portfolios."It's …

    Published on 2/2/2016
  • COMPANY NEWS: U.K. court invalidates Regeneron mouse patents

    Kymab Ltd. (Cambridge, U.K.) said the English High Court revoked two patents from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) protecting VelocImmune mice and humanized mouse antibodies derived from the mice. Regeneron …

    Published on 2/2/2016
  • COMPANY NEWS: Abbott buys diagnostics company Alere

    Abbott Laboratories (NYSE:ABT) is acquiring diagnostics play Alere Inc. (NYSE:ALR) for $56 per share in cash, or about $5.8 billion. Abbott said it will assume or refinance Alere's net debt of $2.6 billion. The …

    Published on 2/1/2016
  • COMPANY NEWS: Avalanche acquires Annapurna

    Avalanche Biotechnologies Inc. (NASDAQ:AAVL) will acquire Annapurna Therapeutics S.A.S. (Paris, France), gaining four preclinical gene therapy programs outside of ophthalmology. Annapurna shareholders will receive 17.6 …

    Published on 2/1/2016
  • COMPANY NEWS: Huya, Eisai strike deal for Chipscreen drug

    Huya Bioscience International LLC (San Diego, Calif.) granted Eisai Co. Ltd. (Tokyo:4523) exclusive rights to HBI-8000 in several Asian territories. Huya has ex-China rights to the drug from Shenzhen Chipscreen …

    Published on 2/1/2016
  • COMPANY NEWS: Portola partners andexanet alfa in Japan

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA) partnered with Bristol-Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE: PFE) to develop and commercialize Portola's andexanet alfa (PRT064445) in Japan. The recombinant …

    Published on 2/1/2016
  • COMPANY NEWS: Aetna, Novartis strike deal on Entresto

    Aetna Inc. (NYSE:AET) told BioCentury on Friday that it struck an outcomes-based pricing deal with Novartis AG (NYSE:NVS; SIX:NOVN) for heart failure drug Entresto sacubitril/valsartan.Novartis agreed to an undisclosed …

    Published on 1/29/2016
  • COMPANY NEWS: Allergan, AZ partner to develop antibiotic

    Allergan plc (NYSE:AGN) said it partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) to develop ATM-AVI, a combination of antibiotics aztreonam and avibactam to treat Gram-negative infections.ATM-AVI was developed under a…

    Published on 1/29/2016
  • COMPANY NEWS: CHMP backs basket of therapies

    EMA's CHMP recommended marketing authorization of three new medicines Thursday and recommended label expansions for Revlimid lenalidomide from Celgene Corp. (NASDAQ:CELG) and Revolade eltrombopag from Novartis AG (NYSE:…

    Published on 1/29/2016
  • COMPANY NEWS: FDA panel to discuss Acadia's Nuplazid for PDP

    FDA's Psychopharmacologic Drugs Advisory Committee will meet on March 29 to discuss an NDA for Nuplazid pimavanserin from Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) to treat Parkinson's disease psychosis. The NDA is …

    Published on 1/29/2016
  • COMPANY NEWS: Gilead promotes Milligan to CEO

    Gilead Sciences Inc. (NASDAQ:GILD) said President and COO John Milligan will be promoted to CEO and will join Gilead's board, effective March 10. Current Chairman and CEO John Martin will become executive chairman. …

    Published on 1/29/2016
  • COMPANY NEWS: Management tracks

    The EMD Serono unit of Merck KGaA (Xetra:MRK) named Gary Zieziula president and managing director for North America. Zieziula was EMD Serono's chief commercial officer. Immuno-oncology company Surface Oncology Inc. (…

    Published on 1/29/2016
  • COMPANY NEWS: Synergy submits plecanatide NDA

    Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) said it submitted an NDA to FDA for plecanatide, a guanylate cyclase C (GCC; GUCY2C) agonist to treat chronic idiopathic constipation (CIC).Last year, plecanatide met the …

    Published on 1/29/2016
  • COMPANY NEWS: Breakthrough designation for AZ's Lynparza in CRPC

    AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA granted breakthrough therapy designation to Lynparza olaparib as monotherapy to treat metastatic castration-resistant prostate cancer. The designation covers CRPC patients …

    Published on 1/28/2016
  • COMPANY NEWS: FDA approves Merck's HCV combo

    FDA approved Zepatier grazoprevir/elbasvir (MK-5172/MK-8742) from Merck & Co. Inc. (NYSE:MRK) with or without ribavirin to treat HCV genotypes 1 and 4 in adults. Merck said Thursday it would launch the drug within seven…

    Published on 1/28/2016
  • COMPANY NEWS: Genentech in-licenses Amgen's AMG 282

    The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) received exclusive global rights from Amgen Inc. (NASDAQ:AMGN) to AMG 282, an antibody against IL-1 receptor-like 1 (IL1RL1; ST2). The antibody prevents IL-33 from…

    Published on 1/28/2016
  • COMPANY NEWS: Neos rises after ADHD approval

    Neos Therapeutics Inc. (NASDAQ:NEOS) gained $3.96 (42%) to $13.38 on Thursday after FDA approved Adzenys XR-ODT (NT-0202) to treat ADHD in patients aged six and older. Chief Commercial Officer Thomas McDonnell said Neos…

    Published on 1/28/2016
  • COMPANY NEWS: Priority Review for Exelixis' cabozantinib in RCC

    Exelixis Inc. (NASDAQ:EXEL) said FDA granted Priority Review to an NDA for a tablet formulation of cabozantinib (XL184) as second-line therapy to treat advanced renal cell carcinoma. Its PDUFA date is June 22. Exelixis …

    Published on 1/28/2016
  • COMPANY NEWS: Massachusetts AG presses Gilead on HCV pricing

    In a letter to Gilead Sciences Inc. (NASDAQ:GILD) Chairman and CEO John Martin, Massachusetts Attorney General Maura Healey said her office is "considering whether Gilead's pricing strategy" for its HCV drugs Sovaldi …

    Published on 1/27/2016
  • COMPANY NEWS: Merck, CRT in deal for PRMT5 inhibitors

    Merck & Co. Inc. (NYSE:MRK) partnered with Cancer Research Technology Ltd. to develop inhibitors of protein arginine methyltransferase 5, which the companies said have potential to treat cancer and non-cancer blood …

    Published on 1/27/2016
  • COMPANY NEWS: Priority Review for Merck's bezlotoxumab

    Merck & Co Inc. (NYSE:MRK) said FDA accepted for filing and granted Priority Review to a BLA for bezlotoxumab (MK-6072) to treat recurrent Clostridium difficile infection. Its PDUFA date is July 23.Merck said EMA is …

    Published on 1/27/2016
  • COMPANY NEWS: NICE backs five cancer drugs, spurns Cyramza

    The U.K.'s NICE recommended a quintet of cancer drugs, including reversing a prior decision on Farydak panobinostat from Novartis AG (NYSE:NVS; SIX:NOVN); however, the agency snubbed stomach cancer compound Cyramza …

    Published on 1/26/2016
  • COMPANY NEWS: FDA accepts BLA for Amgen's Humira biosimilar

    Amgen Inc. (NASDAQ:AMGN) said FDA accepted for review a BLA for ABP 501, a biosimilar of Humira adalimumab from AbbVie Inc. (NYSE:ABBV). Its action date under the Biosimilar User Fee Act (BsUFA) is Sept. 25.Amgen said …

    Published on 1/25/2016
  • COMPANY NEWS: FDA reviewing Valeant's brodalumab

    Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said FDA accepted a BLA for brodalumab (KHK4827) to treat moderate to severe plaque psoriasis. The PDUFA date for the human IgG2 mAb against IL-17 receptor…

    Published on 1/25/2016
  • COMPANY NEWS: Management tracks

    Neurology play Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) named James Owen CMO and SVP of clinical development. He was VP of U.S. clinical affairs at H. Lundbeck A/S (CSE:LUN). Cancer play Clovis Oncology Inc. (NASDAQ:…

    Published on 1/25/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993